Monte Rosa Therapeutics (GLUE) Net Margin (2020 - 2026)
Monte Rosa Therapeutics (GLUE) reported Net Margin of -483.91% for Q2 2026, down 430.90 percentage points from -53.01% a year earlier but up 573.17 percentage points from the prior quarter.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Net Margin (2020 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Monte Rosa Therapeutics' Net Margin came in at -560.76%, down 574.34 percentage points year-over-year; for FY2025, it was -31.21%, up 64.92 percentage points from FY2024.
- By year, Net Margin came in at -96.14% in FY2024.
- Five-year quarterly Net Margin spans a low of -3004.51% in Q1 2024 and a high of 55.20% in Q1 2025.
- Year over year, Net Margin has now declined in each of the last three quarters, with an average year-over-year change of +79.29 percentage points over the last six quarters.
- Per Business Quant data, the three quarters before Q2 2026 came in at -1057.08% (Q1 2026), -1658.00% (Q4 2025) and -212.10% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 30.88% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 21.86% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 21.27% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | -8.04% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 22.65% |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 16.30% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 23.62% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -134.51% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | -1.65% |
| 10 | Monte Rosa Therapeutics | 1.14 Bn | 550.40 Mn | - | -483.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -483.91% |
| Mar 31, 2026 | -1,057.08% |
| Dec 31, 2025 | -1,658.00% |
| Sep 30, 2025 | -212.10% |
| Jun 30, 2025 | -53.01% |
| Mar 31, 2025 | 55.20% |
| Dec 31, 2024 | 22.16% |
| Sep 30, 2024 | -258.89% |
| Jun 30, 2024 | -645.58% |
| Mar 31, 2024 | -3,004.51% |
| Dec 31, 2022 | -1,546.83% |
| Sep 30, 2022 | -2,740.02% |
| Jun 30, 2022 | -4,214.81% |
| Mar 31, 2022 | -16,061.74% |
| Dec 31, 2021 | -180,630.77% |
| Sep 30, 2021 | -152,592.31% |
| Jun 30, 2021 | -131,464.29% |
| Mar 31, 2021 | -204,600.00% |
| Dec 31, 2020 | -218,633.33% |
| Sep 30, 2020 | -327,900.00% |
API Access
Monte Rosa Therapeutics Net Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-margin&ticker=GLUE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-margin", "ticker": "GLUE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-margin&ticker=GLUE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();